Navigation Links
Eisai Receives Action Letter on Fospropofol Disodium Injection for Sedation in Diagnostic or Therapeutic Procedures
Date:7/25/2008

FDA's Not Approvable Letter Outlines Pathway to Potential Approval

WOODCLIFF LAKE, N.J., July 25 /PRNewswire/ -- Eisai Corporation of North America today announced that it has received a not approvable letter from the U.S. Food and Drug Administration (FDA), which outlines a pathway to potential approval of fospropofol disodium for use by appropriately trained physicians. Fospropofol disodium injection has been in review at the FDA for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures.

"We are confident that our continued discussions with FDA will lead to the timely approval of this important new therapy," said Mary Lynne Hedley, PhD, Executive Vice President of Eisai Corporation of North America. "We look forward to working with FDA to help ensure that appropriately trained physicians have this new option for patients. We believe that our clinical data submitted to FDA supports the approval of fospropofol disodium as a potential new option for sedation of patients undergoing important diagnostic or therapeutic procedures."

On May 7, 2008, the FDA Advisory Committee on Anesthetic and Life Support Drugs voted 6 to 3 in favor (with one abstention) of approval of fospropofol disodium injection for use as an intravenous sedative-hypnotic agent for sedation in adult patients undergoing diagnostic or therapeutic procedures. The committee recommended use of fospropofol disodium injection by healthcare providers who are appropriately trained.

About Fospropofol Disodium Injection

Fospropofol disodium injection is a proprietary prodrug of propofol that, after intravenous injection, is converted by an enzyme (alkaline phosphatase) in the body into propofol. Fospropofol disodium injection is a product candidate in development for sedation of adult patients undergoing diagnostic or therapeutic procedures.

About Eisai Corporation of North America

Eis
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Eisai Corporation of North America Announces Appointment of Cynthia Schwalm as President, Eisai Inc.
2. Eisai is Granted Favorable Preliminary Injunction Ruling in Aricept(R) Patent Infringement Lawsuit Against Teva Pharmaceuticals
3. Eisai/Pfizers Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimers Disease
4. Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
5. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in General Surgery
8. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
9. Peregrine Pharmaceuticals Receives Letter from NASDAQ Citing Failure to Regain Compliance with Minimum Bid Price Rule
10. Spherix Receives NASDAQ Bid Price Deficiency Letter
11. Seahorse Bioscience Receives Poster Award from the European Association for the Study of Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2015 VG Life Sciences, Inc., (OTCQB: ... and infectious diseases, announced that the U.S. Patent ... new composition of matter patent covering methods for ... CLIP. U.S. Patent No. 8957031 ... Sciences, VG1177, a synthetic peptide which has the ...
(Date:3/2/2015)... Outside GC, the leading provider of on-demand, ... Debbie Casey as a member of the firm, further ... , Debbie has spent over 20 years in ... Care North America in both legal and business capacities. ... with Outside GC’s growing list of healthcare clients, with ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine” or ... a fraudulent press release disseminated this morning by PR ... Immunovaccine. This press release states that Immunovaccine has entered ... The press release did not originate from Immunovaccine and ... the press release. Please note that all official ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015 ... of the NCATS rare-diseases portfolio " in ... a new financing technique to reduce the risk ... diseases and potentially unlock new levels of funding ... The product of a unique collaboration between scientists ...
Breaking Biology Technology:VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Outside GC Expands Healthcare Team 2Immunovaccine Disclaims Hoax Press Release 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4
... induce stress,but caring for children with diabetes this time ... and caregivers can visit, http://www.abbottdiabetescare.com to participate in ... how to best manage a child,s,diabetes during the holidays, ... ,Diabetes Fit Food, booklet for tips on healthy eating. ...
... REDWOOD CITY, Calif., Nov. 7 Threshold,Pharmaceuticals, Inc. ... for,the third quarter ended September 30, 2007. Net ... million compared to $16.7 million for the third ... development of our hypoxia-activated prodrug,platform for the treatment ...
... 13 at 1:30 p.m. (Pacific); ... at http://www.adventrx.com , SAN DIEGO, Nov. 7 ... research and development company,focused on commercializing proprietary product candidates ... financial results for,the three-month and nine-month periods ended September ...
Cached Biology Technology:New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 2Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 3Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 4Threshold Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 2ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 3ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 4ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 5ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 6ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results 7
(Date:3/2/2015)... Ala. , March 2, 2015  Businesses ... processing. Data protection company Tharon Rankins Enterprises has ... that provides an ultra-safe way for businesses to ... their financial transactions. Beconux is ... Tharon Rankins Enterprises. Functioning similarly to an ATM ...
(Date:2/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/sxwl43/global_2d_gesture ) ... 2D Gesture Recognition Market 2015-2019" report to ... the Global 2D Gesture Recognition market to grow ... 2014-2019 The increased demand for gesture-enabled ... the major trends in the market. The growing ...
(Date:2/12/2015)...   MedNet Solutions , a global life ... systems, has recently bolstered its iMedNet™ ... iMedNet as the eClinical solution of ... consultants.  Building on the Program,s existing benefits (including ... co-marketing opportunities), MedNet,s new and improved program provides ...
Breaking Biology News(10 mins):Personal Data Protection Company Launches New Product 2Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2
... type of brain cancer, undergo neurosurgery to remove the ... largely on how rapidly the cancer recurs. Even though ... it is difficult to determine with certainty whether cancer ... aggressive treatment. Now a team from the University ...
... ACTON, Mass., Jan. 24, 2012 Psychemedics Corporation (NASDAQ: ... global leader for 25 years, announced today that the ... No. 8,084,215, to the company.  This patent focuses on ... without destroying the drugs.  The new patented method can ...
... 23, 2012) - With growing concern that excessive levels of ... pressure, kidney disease and diabetes researchers at the University of ... of Florida, set out to see if two common sweeteners in ... first few hours after ingestion. The study, recently published in ...
Cached Biology News:Team finds new way to image brain tumors and predict recurrence 2Psychemedics Awarded Patent Fundamental To Hair Analysis Drug Testing 2CU School of Medicine researchers look at effects of 2 common sweeteners on the body 2
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... tissue microarrays are derived from frozen embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... slides. Sections are large (3-5mm in diameter) ...
... are derived from Paraffin embedded tissue blocks, ... procedures to ensure the highest quality. Tissues ... one block, sectioned at a thickness of ... Sections are large (3-5mm in diameter) in ...
... Precision-designed for Optimal Microdissection , ... enable the precise and rapid extraction of ... and cytology samples with Laser Capture Microdissection., ... for Downstream Molecular Analysis , All CapSure ...
Biology Products: